3B Future Health Fund

The 3B Future Health Fund is a venture capital fund managed by Helsinn, a Swiss pharmaceutical company, dedicated to early-stage investments in the life sciences sector. Its core mission revolves around identifying and supporting innovative companies that address areas of high unmet patient need, particularly within oncology, rare diseases, and advanced digital health solutions.

Established with a fund size of $140 million, the fund strategically deploys capital into Seed, Series A, and Series B rounds. This financial commitment enables 3B Future Health Fund to back promising ventures through critical early development phases. As of recent data, the fund has built a focused portfolio, having made approximately 15 investments across various therapeutic and technological domains.

Beyond capital provision, 3B Future Health Fund leverages Helsinn's extensive pharmaceutical expertise, robust R&D capabilities, and global network. This strategic partnership approach aims to provide significant value-add to its portfolio companies, accelerating the translation of scientific breakthroughs into tangible patient benefits and market-ready solutions.

The fund's investment philosophy emphasizes long-term collaboration and a hands-on approach, working closely with founders to navigate the complex landscape of healthcare innovation. This collaborative model is designed to foster sustainable growth and maximize the impact of its portfolio companies on patient care.

Typically, 3B Future Health Fund's initial check sizes range from approximately $1 million for promising seed-stage opportunities to around $8 million for more mature Series A or early Series B rounds. This flexible investment range allows the fund to engage with a broad spectrum of early-stage innovation, from foundational research to clinical development.